ID   PC-9/WZR11
AC   CVCL_DG32
SY   WZR11
DR   cancercelllines; CVCL_DG32
DR   GEO; GSM925741
DR   Progenetix; CVCL_DG32
DR   Wikidata; Q54938507
RX   PubMed=22961667;
CC   Population: Japanese.
CC   Selected for resistance to: ChEBI; CHEBI:49668; Gefitinib (ZD1839; Iressa).
CC   Selected for resistance to: ChEBI; CHEBI:61400; WZ4002.
CC   Sequence variation: Mutation; HGNC; 3236; EGFR; Simple; p.Glu746_Ala750del (c.2235_2249del15); ClinVar=VCV000163343; Zygosity=Unspecified (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Homozygous (from parent cell line).
CC   Derived from site: Metastatic; Lymph node; UBERON=UBERON_0000027.
DI   NCIt; C3512; Lung adenocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_DH34 ! PC-9/GR4
SX   Male
AG   45Y
CA   Cancer cell line
DT   Created: 13-07-16; Last updated: 05-10-23; Version: 13
//
RX   PubMed=22961667; DOI=10.1158/2159-8290.CD-12-0103;
RA   Ercan D., Xu C.-X., Yanagita M., Monast C.S., Pratilas C.A., Montero J.,
RA   Butaney M., Shimamura T., Sholl L.M., Ivanova E.V., Tadi M., Rogers A.,
RA   Repellin C., Capelletti M., Maertens O., Goetz E.M., Letai A.G.,
RA   Garraway L.A., Lazzara M.J., Rosen N., Gray N.S., Wong K.-K.,
RA   Janne P.A.;
RT   "Reactivation of ERK signaling causes resistance to EGFR kinase
RT   inhibitors.";
RL   Cancer Discov. 2:934-947(2012).
//